Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

Last updated: March 9, 2026
Sponsor: Katerina M. Antoniou
Overall Status: Active - Recruiting

Phase

N/A

Condition

Idiopathic Pulmonary Fibrosis

Treatment

Quercetin (dietary supplement)

Usual treatment

Clinical Study ID

NCT07466420
247/23-12-2025
  • Ages > 18
  • All Genders

Study Summary

Fibrotic interstitial lung diseases (F-ILDs), including both idiopathic pulmonary fibrosis (IPF) and non-IPF, are chronic and progressive lung diseases characterized by excessive scarring of lung tissue, leading to declining lung function, respiratory failure, and high mortality, despite the currently approved antifibrotic treatment. While its exact cause remains unknown, pulmonary fibrosis is strongly linked to aging, genetic predisposition, environmental factors, and cellular senescence. Ongoing research aims to identify reliable biomarkers and develop targeted treatments to enhance patient outcomes.

This randomized controlled trial will examine the effects of quercetin supplementation (500 mg/day for two 12-week cycles, with one 8-week washout periods) on telomere length, senescence-associated secretory phenotype (SASP) factors, and lung function in patients with IPF and F-ILDs. A total of 100 patients will be recruited, with half receiving quercetin (despite their standard of care therapy) and the other half receiving standard care (SOC). Primary outcomes will include changes in telomere length, SASP protein levels (IL-6, MMPs), fractional exhaled nitric oxide (FeNO), spirometry (FVC decline), and oscillometry measurements. Additionally, quality of life will be assessed using the L-IPF Questionnaire.

This study aims to explore quercetin's potential to reduce fibrosis, decrease inflammation, and improve lung function in F-ILDs, offering new insights into potential novel strategies for F-ILD management.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligibleto participate in the study.

  • The use of the approved standard of care antifibrotic therapy, either nintedanib orpirfenidone, and immunosuppressive therapy will be allowed as standard of care.

Exclusion

Exclusion Criteria:

  • Subjects with a result of FeNO>25 ppb will be excluded from the study to ensure thatno other pulmonary diseases, such as asthma, are present.

  • Patients who do not initiate quercetin within the first week after their baselinevisit.

Study Design

Total Participants: 100
Treatment Group(s): 2
Primary Treatment: Quercetin (dietary supplement)
Phase:
Study Start date:
January 26, 2026
Estimated Completion Date:
January 31, 2029

Connect with a study center

  • Respiratory Department, University Hospital of Heraklion, School of Medicine, University of Crete

    Heraklion, Crete 71500
    Greece

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.